Modality-Agnostic Drug Discovery With Cullinan Oncology's Nadim Ahmed
Call it fortuitous, good planning, instinct, or a combination of all three, but Nadim Ahmed's educational foundation— earned before the IT/Biology combination was cool— is serving him well as CEO at Cullinan Oncology. On this episode of the Business of Biotech, Ahmed shares his story and that of Cullinan Oncology's drug discovery efforts, which have yielded a wide range of multi-modal candidates spanning a range of cancer indications. Our discussion digs into the company's transition from R&D to the clinic, how its built an uncommonly comfortable cash position through partnership, and its ambition to become a fully-integrated commercial-stage biotech.
Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!
